6.jpeg
SERVICE INTRODUCTION

Payer Environment Assessment

The payer environment is always evolving. Understanding what it looks like today, and how it might look tomorrow, is crucial. And that’s true if you’re launching a new product, introducing a new indication or re-positioning an established therapy.

You need a realistic assessment of the best achievable price and access situation. Along with the reassurance that these can be maintained.

CASE STUDY
Assessment to inform corporate strategy based on P&MA issues with biosimilars

Our client was the Head of Global Pricing and Market Access in a mid-sized EU based global company with a successful background in cardiovascular disease and biologicals. They wanted to explore a shift in business strategy towards the development and marketing of branded biosimilars.

READ THE CASE STUDY HERE
WHERE WE FIT IN
 

Why assess the payer environment?

Asset 10.png
UNDERSTANDING ENVIRONMENTS
 

Whatever your product’s stage of development, you need to understand who is ultimately going to pay for it.

A clear view of the payer landscape helps you optimally position a new product, or decide whether to launch an existing drug in a new indication.

It also supports investment decisions. And that includes how much – if anything – you should pay for an in-licensing opportunity.

HOW WE STAND OUT

RJW&partners' expert team will develop a bespoke strategy based on your specific product and market needs.

We use various approaches, including interviews and payer advisory boards, secondary research and analysis, all backed by expert team members with experience working with – and within – payers and manufacturers across multiple markets.

Our materials are delivered in a clear, user-friendly and fully-referenced format.

CASE STUDY

Assessment of Future Payer Environment for Pipeline Products using a Payer Advisory Board

Our client, the global pricing and market access function of a specialist biopharmaceutical orphan drug company, wanted to hold a payer advisory board to review its entire pipeline.

The pipeline contained six products at various stages of development. Their indications spanned a range of therapeutic areas and each faced very different challenges.

READ THE CASE STUDY HERE